Aim: The purpose of this study was to evaluate the safety and efficacy of aripiprazole in adolescents with schizophrenia (SCZ) in Japan.
with SCZ. 1 In the USA, aripiprazole, risperidone, olanzapine, quetiapine, and paliperidone are approved for treating SCZ in adults and adolescents. 3 In Japan, these atypical antipsychotics are approved for treating SCZ in adults only.
Aripiprazole is pharmacologically distinct from other antipsychotics, acting as a partial agonist at the dopamine D 2 and D 3 and serotonin 5-HT 1A receptors and as an antagonist at the 5-HT 2A receptors. 4, 5 In the USA, aripiprazole is approved for the treatment of SCZ in adult and adolescent patients aged 13-17 years, for bipolar mania in adult and pediatric patients aged 10-17 years, for irritability associated with autism spectrum disorder in patients aged 6-17 years, for Tourette's disorder in patients aged 6-18 years, and for adjunctive treatment of major depressive disorder in adults. In Japan, aripiprazole is approved for the treatment of SCZ, bipolar mania, and irritability associated with autism spectrum disorder in patients aged 6-17 years, and for adjunctive treatment of major depressive disorder. Because of its unique mechanism of action, aripiprazole may have a more favorable safety profile than other antipsychotics in pediatric and adolescent patients with mental health disorders. 3 Aripiprazole (10 and 30 mg/day) was shown to be efficacious while being generally safe and well tolerated for the treatment of adolescents (aged 13-17 years) with SCZ in the 6-week, double-blind, randomized, placebo-controlled global study and the 52-week, randomized, placebo-controlled withdrawal study. 6, 7 However, because of a paucity of data on the Japanese patient population, a phase 3 clinical study of aripiprazole in Japan was needed. It is important to note that placebo-controlled studies have been the standard approach for evaluating the efficacy of a medication for the treatment of SCZ; however, such studies are of particular concern because of the increased impact on poor prognosis that accompanies treatment with placebo for adolescents with SCZ. 8 Furthermore, it is difficult to enroll adolescent patients with SCZ in placebo-controlled trials in Japan. Additionally, there are no atypical antipsychotics approved for the treatment of adolescents with SCZ in Japan. Therefore, we designed a dosecomparison study of three different doses of aripiprazole (2, 6-12, and 24-30 mg/day) without placebo. Because SCZ is a chronic illness requiring long-term therapy, a long-term study was needed to investigate the safety of aripiprazole in Japanese adolescents. We therefore also planned a 52-week long-term study.
We report results from the first multicenter, randomized, double-blind, dose comparison of three different doses of aripiprazole, a phase 3 study that evaluated the 6-week efficacy and safety of aripiprazole in adolescents (aged 13-17 years) with SCZ in Japan. The safety and efficacy profiles of aripiprazole in these adolescents were further evaluated in a 52-week, flexible-dose, open-label extension (OLE) study of aripiprazole (initial dose: 2 mg/day, maintenance dose: 6-24 mg/day, maximum dose: 30 mg/day).
METHODS
The 6-week, randomized, double-blind, dosecomparison study (ClinicalTrials.gov: NCT01942161) was conducted at 83 centers in Japan from September 2010 to November 2014. The 52-week, flexible-dose, OLE study (ClinicalTrials.gov: NCT01942148) was conducted at 80 centers in Japan from October 2010 to November 2015. These studies were conducted in compliance with the International Conference on Harmonisation Good Clinical Practice Consolidated guideline, local laws, and regulatory requirements in Japan, and the protocols were approved by the institutional review board of Hiroshima City Funairi Citizens Hospital and conformed to the provisions of the Declaration of Helsinki. Written informed consent was obtained from all patients' guardians or legal representatives, and written assent was obtained from each adolescent patient before any study-related procedures were performed.
Six-week, randomized, double-blind, dosecomparison study
Patients
Patients who were deemed appropriate candidates by their treating physicians were screened for eligibility within 4 weeks of randomization. Eligible patients met the following inclusion criteria: (i) DSM-IV-TR diagnosis of SCZ 9 and confirmation of the SCZ diagnosis by means of the Mini-International Neuropsychiatric Interview for Children and Adolescents 10 ; (ii) boys or girls aged 13-17 years; and (iii) a baseline Positive and Negative Syndrome Scale (PANSS) total score of 70 or higher.
Patients with DSM-IV-TR diagnostic criteria other than SCZ, intellectual disability, thyroid dysfunction, or a history of treatment with clozapine or aripiprazole were excluded, as were patients who had been admitted involuntarily. In addition, we also excluded: patients whose illness had been previously resistant to more than two different antipsychotics at adequate doses for more than 4 weeks; patients with impairment of hepatic, renal, cardiac, or hematologic functions; patients who had a complication or history of epilepsy, organic brain disease, diabetes, suicide attempt, suicidal ideation, self-harm, neuroleptic malignant syndrome, tardive dyskinesia, adynamic ileus, or water intoxication; patients who had a Clinical Global Impression-Severity (CGI-S) of Suicidality (CGI-SS) Part 1 score of 2 or higher; patients who had a complication of parkinsonism; female patients who were pregnant or breastfeeding or did not agree to birth control; and patients who screened positive for illegal drugs or who had substance dependence (DSM-IV-TR criteria) within 3 months before screening.
Study design
Eligible patients were randomized in a 1:1:1 ratio to receive 2 mg/day, 6-12 mg/day, or 24-30 mg/day of aripiprazole for 6 weeks. The study drug was administered once daily. Investigators, sub-investigators, and patients were blinded to the treatment randomization code throughout the study. Clinicians prescribed a study drug for a patient in ascending sequence of the drug allocation number. Based on the effective and well-tolerated dosing schedule used in the previous study 6 and the dose range of aripiprazole for adults in Japan (starting dose: 6-12 mg/day, target dose: 6 mg/day to 24 mg/day, maximum dose: 30 mg/day), 11 eligible patients received aripiprazole 2, 6-12, or 24-30 mg/day. In the 2-mg group, aripiprazole was administered at 2 mg/day for 42 days. In the 6-12-mg group, aripiprazole was titrated from a starting dose of 2 mg/day to 6 mg/day on day 3, and was administered at 6 or 12 mg/day between days 15 and 42. Patients in the 24-30-mg group also began at 2 mg/day; the dose was then increased every 2 days to 6 mg/day, 12 mg/day, 18 mg/day, and 24 mg/day, and aripiprazole was administered at 24 or 30 mg/day between days 15 and 42. In the 6-12-mg and the 24-30-mg groups, from day 15 onward, the dose used at that time (6 or 24 mg/day) was up-titrated to the next higher dose (12 or 30 mg/day) according to the patient's tolerability when the Clinical Global Impression-Improvement (CGI-I) score was assessed as ≥4. The dose could be down-titrated to 6 or 24 mg/day at the clinician's discretion according to the patient's tolerability of the dose (12 or 30 mg/day). After dose reduction, up-titration was not permitted.
Patients were required to discontinue antipsychotics (except long-acting injectables) after the first dose of the study drug. Long-acting injectable antipsychotics must have been discontinued for at least 3 months before the first dose of the study drug. Stimulants, including medications for attentiondeficit hyperactivity disorder, must have been discontinued for at least 4 weeks before the first dose of the study drug, and mood stabilizers, antidepressants, anticonvulsants, hypnotics/anxiolytics (except for short-and very-short-acting medications), supplements containing centrally acting substances (tryptophan and St. John's wort), antiparkinson medications (except biperiden and trihexyphenidyl), beta-blockers, adrenaline, and electroconvulsive therapy must have been discontinued for at least 3 days before the first dose of the study drug. Previously administered medications, including shortand very-short-acting hypnotics (zopiclone, triazolam, triclofos sodium, brotizolam, lormetazepam, and rilmazafone), and short-acting anxiolytics (etizolam, clotiazepam, and flutazolam) were allowed during the study. One anticholinergic antiparkinson medication (biperiden or trihexyphenidyl) to treat extrapyramidal symptoms (EPS) was allowed during the study, with prohibition of medication change. Treatment with the permitted hypnotics/anxiolytics within 4 h or with the permitted antiparkinson medication within 12 h before efficacy ratings or administration of movement scales was prohibited.
Efficacy assessments
The primary efficacy endpoint was the mean change from baseline to week 6 (last observation carried forward [LOCF]) in the total PANSS score. 12 The secondary efficacy measures included the mean change from baseline in the PANSS Positive, Negative, and General Psychopathology subscale scores. 12 The secondary measures also included the CGI-I and CGI-S scale scores 13 and the Children's Global Assessment Scale (CGAS) score.
14 PANSS 20%, 30%, and 50% responders were defined as patients who achieved a 20%, 30%, or 50% reduction from baseline in the PANSS total score, respectively. CGI-I responders were defined as patients who achieved a CGI-I score of ≤2. PANSS remission was defined as a score of ≤3 on all of the following eight PANSS items: P1, P2, P3, N1, N4, N6, G5, and G9. 15 PANSS and CGI-S were assessed on days 1, 8, 15, 22, 29, and 43. CGI-I was assessed on days 8, 15, 22, 29, and 43. CGAS was assessed on days 1 and 43.
Safety assessments
Safety evaluations included assessment of treatment-emergent adverse events (TEAE), clinical laboratory tests, vital signs, bodyweight, electrocardiogram (ECG), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), 16 Abnormal Involuntary Movement Scale (AIMS), 17 Barnes Akathisia Rating Scale (BARS), 18 and CGI-SS. CGI-SS was assessed on days 1, 8, 15, 22, 29, and 43. DIEPSS, AIMS, and BARS were assessed on days 1, 29, and 43. Clinical laboratory tests, vital signs, and bodyweight were assessed at screening and on days 8, 15, 29, and 43. ECG was assessed at screening and on day 43.
Statistical analyses
Efficacy data were analyzed for all randomized patients who received one or more doses of the study drug and had both baseline and at least one post-baseline efficacy measurement. Efficacy measures were calculated using the LOCF approach. Efficacy results were also summarized using the observed case (OC) approach.
Safety data were analyzed for all randomized patients who received one or more doses of the study drug and had at least one post-baseline safety measurement. Safety measures were calculated using the OC approach.
Efficacy endpoints (PANSS total score, PANSS subscale scores [Positive, Negative, and General Psychopathology], CGI-S score, and CGAS score) were assessed using an analysis of covariance (ANCOVA) model with treatment group as a factor and baseline score as a covariate. The CGI-I endpoint was assessed using an ANCOVA model with treatment group as a factor. The least square means derived from this model were used for comparing the 2-mg group with the 6-12-mg group or the 24-30-mg group. For the primary efficacy endpoint, a nominal overall significance level of 0.05 (two-tailed) was used in testing the statistical significance of these two comparisons. The Hochberg procedure was used to account for multiplicity in testing the two comparisons, with the following criteria: if both P-values were ≤ 0.05, statistical significance was declared for both comparisons; if the larger of the two P-values was > 0.05, statistical significance was only declared for the comparison providing the smaller P-value of ≤ 0.025.
Sample sizes with 33 patients in each treatment group were determined based on feasibility at 25 study centers for 4 years in Japan. Aripiprazole was deemed effective and the study was considered to have met its primary endpoint if an improvement of ≥5 points in the primary efficacy analysis was achieved in the 6-12-mg group relative to the 2-mg group. The previous 6-week global study had a 5.5-point difference in the PANSS total score and an 18.7-point SD between aripiprazole 10 mg/day and placebo. 6 If the present 6-week study showed the same level of difference in the PANSS total score and SD as the previous one between the 6-12-mg group and the 2-mg group with 33 patients in each treatment group, it would have a probability of 55% to detect a difference of ≥5 points and 22% power to detect a significance level of 0.05.
Fifty-two-week, flexible-dose OLE Study design
Patients aged 13-17 years who had completed the previous 6-week study were eligible to participate in the 52-week OLE. Written informed consent was obtained from all patients' guardians or legal representatives, and written assent was obtained from each adolescent patient before any study-related procedures were performed. On day 1 of the OLE, all patients started with open-label aripiprazole at a dose of 2 mg/day. On day 3, the dose was increased to 6 mg/day. From day 9, the dose was adjusted to 6-24 mg/day based on efficacy and tolerability, and the 24-mg/day dose was up-titrated to 30 mg/day if the efficacy was not sufficient. The dose could be up-or down-titrated, but down-titration below 6 mg/day was not permitted. 
Efficacy and safety assessments
Long-term efficacy, safety, and tolerability of aripiprazole therapy in adolescents were assessed for up to an additional 52 weeks and summarized descriptively. Efficacy and safety evaluations in the 6-week study were also assessed in the OLE. PANSS, CGI-S, CGI-I, bodyweight, vital signs, CGI-SS, and DIEPSS were assessed at weeks 1, 2, 4, 8, 12, 16, 24, 32, 40, 48, and 52; CGAS, AIMS, and BARS were assessed at weeks 24 and 52; laboratory tests and ECG were assessed at weeks 8, 24, and 52; height was assessed at the OLE baseline and at weeks 24 and 52. Data at week 6 in the 6-week study, except height, were used as the OLE baseline data.
Statistical analyses
Efficacy data were analyzed for all patients who received one or more doses of the study drug and had at least one post-dose efficacy measurement. Efficacy measures were calculated using the LOCF approach. Efficacy results were also summarized using the OC approach. Safety data were analyzed for all patients who received one or more doses of the study drug and had at least one post-dose safety measurement. Safety measures were calculated using the OC approach. TEAE other than those reported in the previous 6-week study were evaluated during the OLE.
RESULTS

Patients
Six-week study A total of 106 patients were randomized to treatment with aripiprazole 2 mg/day (n = 35), 6-12 mg/day (n = 30), or 24-30 mg/day (n = 41); all randomized patients received one or more doses of the study drug and were included in the efficacy and safety datasets. In the 2-mg group, one patient had efficacy data for day 1 only. Patient disposition is shown in Figure 1 . Overall, 77.1% (27/35), 80.0% (24/30), and 85.4% (35/41) of patients completed treatment in the 2-mg/day, 6-12-mg/day, and 24-30-mg/day groups, respectively ( Fig. 1) . Demographic and clinical characteristics at baseline are shown in Table 1 . The mean duration of treatment was 35.6 days for the 2-mg group, 36.3 days for the 6-12-mg group, and 37.7 days for the 24-30-mg group. At the endpoint, the groups assigned to aripiprazole 6-12 mg/day and 24-30 mg/day received mean (SD) daily doses of 8.2 (2.9) mg and 25.5 (2.6) mg, respectively. The rate of patients at an adherence rate of 70% or higher was 100% in all groups. Hypnotics/anxiolytic agents (aripiprazole 2 mg/day, n = 13 [37.1%]; aripiprazole 6-12 mg/day, n = 15 [50.0%]; aripiprazole 24-30 mg/day, n = 19 [46.3%]) were used concomitantly during the study.
OLE
Most (79% [68/86]) of the patients who completed the 6-week study received one or more doses of the study drug in the OLE, and these patients were included in the efficacy and safety datasets. Patient disposition is shown in Figure 1 . Demographic and clinical characteristics at baseline are shown in Table 1 . The mean (SD) duration of treatment was 275.1 (128.6) days. The mean (SD) daily doses of aripiprazole for the whole treatment and at the endpoint were 10.7 (6.1) mg and 12.7 (7.7) mg, respectively. The last dose of aripiprazole was distributed as follows: 2 mg/day, n = 0 (0%); 6 mg/day, n = 31 (45.6%); 12 mg/day, n = 14 (20.6%); 18 mg/day, n = 11 (16.2%); 24 mg/day, n = 8 (11.8%); and 30 mg/day, n = 4 (5.9%). The rate of patients at an adherence rate of 70% or higher was 95.6% (n = 65).
Efficacy Six-week study
The efficacy data are shown in Table 2 and Figure 2 . In the analysis of the PANSS total score change from baseline to week 6, the primary efficacy objective was not achieved because the difference from the 2-mg group was not ≥5 points in the 6-12-mg group. The difference in least square mean change from baseline to week 6 in the PANSS total score was 3.1 (95% confidence interval [CI], −6.4 to 12.5; P = 0.522) for the 6-12-mg group versus the 2-mg group and −2.0 (95% CI, −10.7 to 6.6; P = 0.641) for the 24-30-mg group versus the 2-mg group. For the secondary outcome, which can be considered only exploratory because the primary efficacy objective was not achieved, a significant improvement in each score was not observed in either the 6-12-mg or the 24-30-mg group when compared with the 2-mg group. Efficacy results using the OC (the 2-mg group, n = 27; the 6-12-mg group, n = 24; and the 24-30-mg group, n = 35) are shown in Table S1 .
OLE
The efficacy data are shown in Table 2 . On average, numerical improvements for the PANSS total and CGI-S scores in the 6-week study were maintained and continued to indicate improvement over the course of 52 weeks of flexible-dose aripiprazole treatment. Efficacy results using the OC (n = 41) are shown in Table S1 .
Safety
Six-week study A summary of the TEAE is shown in Table 3 . The most common (≥20% patients in any group) TEAE were nausea, akathisia, insomnia, and somnolence. Most TEAE were mild or moderate in severity. There were no deaths. Serious TEAE were reported in three patients; these included attempted suicide (n = 1 each in the 6-12-mg and the 24-30-mg groups), worsening of SCZ (n = 1 in the 6-12-mg group), and anxiety (n = 1 in the 24-30-mg group). Of the two patients in the 2-mg group who discontinued due to TEAE, one discontinued because of worsening of SCZ, and the other because of nausea. Of the three patients in the 6-12-mg group who discontinued due to TEAE, one discontinued because of worsening of SCZ, one discontinued because of vomiting, and one discontinued because of worsening of SCZ and attempted suicide. Of the five patients in the 24-30-mg group who discontinued due to TEAE, one discontinued because of nausea, one discontinued because of sedation, one discontinued because of malaise and somnolence, one discontinued because of malaise and abdominal discomfort, and one discontinued because of restless legs syndrome, dysesthesia, dysarthria, and somnolence.
The percentage of EPS-related TEAE was 22.9% (8/35) in the 2-mg group, 23.3% (7/30) in the 6-12-mg group, and 58.5% (24/41) in the 24-30-mg group. The most common TEAE that occurred at an incidence of 10% or higher in any group were akathisia, tremor, and salivary hypersecretion (Table 3) . Most of those TEAE were mild in severity, and no patients experienced a severe TEAE. Mean changes from baseline to week 6 (OC) in the Mean changes from baseline to week 6 in bodyweight, body mass index (BMI), total cholesterol, fasting triglyceride, fasting glucose, and prolactin values are shown in Table 4 . In all groups, there were no clinically meaningful changes in weight, BMI, total cholesterol, fasting triglycerides, or fasting glucose (Table 4) . Mean (SD) prolactin levels at baseline were 29.6 (26.3) ng/mL for the 2-mg group, 28.9 (23.9) ng/mL for the 6-12-mg group, and 39.1 (40.9) ng/mL for the 24-30-mg group, and those at week 6 (OC) were 6.9 (4.6) ng/mL for the 2-mg group, 4.2 (3.4) ng/mL for the 6-12-mg group, and 6.8 (13.4) ng/mL for the 24-30-mg group. There were no clinically meaningful changes in the other clinical laboratory tests, vital sign assessments, or ECG, with no clinically meaningful changes from baseline to week 6 in the CGI-SS Part 1 score in any of the groups.
OLE
A summary of the TEAE is shown in Table 3 . The most common (≥20% patients in any group) TEAE were nasopharyngitis and somnolence. Most TEAE were mild or moderate in severity. There were no deaths. Among the reported serious TEAE, worsening of SCZ was observed in five of 68 (7.4%) patients, and attempted overdose, decreased appetite, delusions, hallucinations, and suicidal ideations were each observed in one of 68 (1.5%) patients; one patient experienced worsening of SCZ, suicidal ideation, and decreased appetite; and another patient experienced delusions and hallucinations. In the 52-week OLE, the initial, maintenance, and maximum doses of aripiprazole were 2 mg/day, 6-24 mg/day, and 30 mg/day, respectively. Data are expressed as mean (SD) except where specified otherwise.
The reasons for discontinuation due to TEAE in 10 of 68 (14.7%) patients were worsening of SCZ (n = 5); worsening of SCZ and suicidal ideation (n = 1); suicidal ideation, delusions, hallucinations, and depression (n = 1); malaise (n = 1); gaze palsy (n = 1); and decreased weight and decreased appetite (n = 1). The percentage of EPS-related TEAE was 26.5% (18/68). These TEAE were mild or moderate in severity. The most common EPS-related TEAE were akathisia and tremor (Table 3) . Mean changes in the DIEPSS, AIMS, and BARS scores from OLE baseline to week 52 (OC) were small.
Mean changes from OLE baseline to week 52 (OC) in bodyweight, BMI, total cholesterol, fasting triglyceride, fasting glucose, and prolactin values are shown in Table 4 . There were no unexpected safety signals based on these clinical laboratory results. The mean (SD) change in height from OLE baseline to week 52 (n = 40, OC) was 1.04 (1.58) cm. Mean (SD) changes from OLE baseline to week 52 (OC) in Z-scores for height (n = 40), weight (n = 41), and BMI (n = 40) were 0.03 (0.23), 0.12 (0.62), and 0.13 (0.59), respectively. Mean (SD) prolactin levels were 6.1 (9.9) ng/mL at baseline (n = 68) and 6.3 (8.7) ng/mL at week 52 (n = 41, OC). There were no unexpected safety signals based on the other clinical laboratory tests, vital sign assessments, or ECG, with no change from OLE baseline to week 52 in the CGI-SS Part 1 score. In the 52-week OLE, the initial, maintenance, and maximum doses of aripiprazole were 2 mg/day, 6-24 mg/day, and 30 mg/day, respectively. Data are expressed as LS mean changes (SE) from baseline to week 6 for the 6-week double-blind study or mean changes (SD) from baseline (data at week 6 in the 6-week double-blind study) to week 52 for the 52-week OLE, except where specified otherwise. † Data are expressed as LS mean (SE) at week 6 for the 6-week double-blind study or mean (SD) at week 52 for the 52-week OLE. ‡ Data are expressed as n (%). § n = 33. ¶ n = 29.
Remission is defined as a score of ≤3 on all of the following eight PANSS items: P1, P2, P3, N1, N4, N6, G5, and G9. CGI-I improvement is defined as a score of 1 or 2. CGAS, Children's Global Assessment Scale; CGI-I, Clinical Global Impression-Improvement; CGI-S, Clinical Global Impression-Severity; LOCF, last observation carried forward; LS, least square; OLE, open-label extension; PANSS, Positive and Negative Syndrome Scale; SE, standard error.
DISCUSSION
To our knowledge, this is the first study with aripiprazole conducted to date in adolescents with SCZ in Japan. Aripiprazole at doses of 2, 6-12, and 24-30 mg/day was efficacious in ameliorating the symptoms of SCZ. Considerable improvement was observed in the 2-mg group, and the 6-12-mg group failed to achieve an improvement of ≥5 points from the 2-mg group for the primary analysis of change in PANSS total score from baseline to week 6. Thus, this study did not achieve the primary efficacy endpoint, and no clear conclusions can be drawn regarding the efficacy of the various doses of aripiprazole based on these data. The reason for the no significant differences for the primary efficacy in the 6-12-mg and 24-30-mg groups compared to the 2-mg group cannot be determined with certainty, and it could be a combination of several factors. In this study, the 2-mg group was used instead of placebo. The sample size in each treatment group was about 1/3 of the previous study. 6 These may be the main factors for the result. The numerical improvement attained in the PANSS total score during the 6-week study was maintained or increased over the course of the 52-week flexible-dose OLE, and many treated patients achieved remission at week 52. This tendency was consistent with the previous 26-week double-blind study. 2 In this 6-week study, the treatment groups had high study completion rates, indicating good overall tolerability and improvement in symptoms of SCZ. This tendency was consistent with the previous 6-week double-blind study. 6 In our study, the incidence rates of nausea, akathisia, tremor, and salivary hypersecretion in the 6-12-mg group were lower than those in the 24-30-mg group. In the previous study, the incidence rates of akathisia, extrapyramidal disorder, somnolence, and tremor in the aripiprazole 10-mg group were lower than those in the 30-mg group. 6 It appears that the incidence rates of these TEAE with different doses of aripiprazole may vary, implying the need for tailored treatment based on individual patient response.
Atypical antipsychotics vary in their tendency to cause weight gain, dyslipidemia, and disturbances in glycemic control. Aripiprazole appeared to have a low propensity for weight gain or adverse metabolic effects in this study. Findings from the current studies are generally comparable to those from previous short-and long-term studies of aripiprazole in adolescents with SCZ, which showed minimal effects of aripiprazole on weight, lipids, or glucose. 2, 6 Hyperprolactinemia has been generally reported with antipsychotic therapy. The effects of hyperprolactinemia are related to amenorrhea, breast enlargement/engorgement, galactorrhea, decreased libido, and erectile dysfunction. 19 All aripiprazole dose groups demonstrated a reduction from baseline in prolactin concentrations in the 6-week study, and these were maintained over the course of the 52-week flexible-dose OLE. This tendency was consistent with that in the previous studies, though the clinical consequences are unknown. 2, 6, 20 This prolactin concentration decrease with aripiprazole may be related to its dopamine D 2 receptor partial agonist property, which is thought to mimic the inhibitory action of dopamine on pituitary prolactin secretion. 20, 21 In a meta-analysis of randomized controlled studies comparing aripiprazole with pooled antipsychotics in mainly Japanese adult patients with SCZ, aripiprazole was associated with a lower risk of weight gain, hyperprolactinemia, metabolic syndrome, and EPS compared with the pooled antipsychotics. 22 Safety data from our studies suggest that the safety profile of aripiprazole in Japanese adolescents is similar to that in Japanese adults with SCZ.
This study design had no placebo arm, thus limiting detection of drug-placebo differences in the In the 52-week OLE, the initial, maintenance, and maximum doses of aripiprazole were 2 mg/day, 6-24 mg/day, and 30 mg/day, respectively. Data are expressed as n (%). For the OLE, TEAE other than those reported in the previous 6-week study were evaluated as TEAE in the OLE. OLE, open-label extension; TEAE, treatment-emergent adverse event. present study. To our knowledge, there are no reports about placebo-controlled studies for atypical antipsychotics in adolescents with SCZ in Japan. These study results highlight the need for employing a placebo-controlled methodology in treatment studies with this adolescent population. Patients with mild severity (PANSS total score of under 70) were excluded in this study, which limits the generalizability.
In conclusion, this randomized, 6-week, doubleblind study and the subsequent 52-week OLE suggest that aripiprazole would be safe and well tolerated for adolescents with SCZ in Japan.
